



(51) International Patent Classification:

C07D 215/12 (2006.01) *C07C 215/08* (2006.01)
A61K 31/131 (2006.01) *C07C 215/12* (2006.01)
A61K 31/47 (2006.01) *C07F 9/09* (2006.01)
A61K 31/661 (2006.01) *C07F 9/38* (2006.01)
A61K 31/662 (2006.01)

(30) Priority Data:

61/476,367 18 April 2011 (18.04.2011) US

(71) Applicant (for all designated States except US): **ALLERGAN, INC.** [US/US]; 2525 Dupont Drive, Irvine, California 92612 (US).

(21) International Application Number:

PCT/US2012/033459

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TAKEUCHI, Janet A.** [US/US]; 8195 E. Bailey Way, Anaheim, California 92808 (US). **LI, Ling** [US/US]; 52 Marlehead, Irvine, California 92620 (US). **IM, Wha Bin** [US/US]; 70 Palatine, Apt. #305, Irvine, California 92612 (US).

(22) International Filing Date:

13 April 2012 (13.04.2012)

(25) Filing Language:

English

(26) Publication Language:

English


(74) Agents: **ENE, Doina** et al.; Allergan, Inc., 2525 Dupont Drive, Irvine, California 92612 (US).

[Continued on next page]


(54) Title: SUBSTITUTED BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS

Figure 1

**Lymphopenia induced
by S1P1 agonists (10mg/Kg) in Mice
(24, 48 hours)**



(57) Abstract: The present invention relates to novel substituted bicyclic methyl amine derivatives of formula (I), wherein A, L₁, L₂, R¹ to R⁷ and a to c are as defined in claim 1, compositions thereof and their use in the treatment of diseases related to the modulation of sphingosine-1-phosphate receptors.





(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD,

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))